Product Images Losartan Potassium 25 Mg

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Losartan Potassium 25 Mg NDC 72789-282 by Pd-rx Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image001 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 01

image001 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 01

image002 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 02

image002 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 02

This text likely represents data from a clinical study evaluating two different medications, Atenolol and Losartan potassium. The study tracked the percentage of patients who achieved a primary endpoint over the course of 66 months. An adjusted risk reduction of 13% was observed with Losartan potassium compared to Atenolol. The p-value of this observation is 0.021, indicating statistical significance.*

image003 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 03

image003 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 03

This appears to be a chart showing the percentage of patients who experienced fatal or non-fatal stroke during a study that spanned over 66 months. The chart indicates that 6% of patients experienced a stroke. Additionally, it shows the percentage of patients who were taking either atenolol or losartan potassium during the study. The numbers beside the drug names may indicate the percentage of patients taking each drug at different points in time during the study.*

image004 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 04

image004 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 04

The text seems to be a report of a study on the effectiveness of Losartan Potassium and Atenolol in reducing the incidence of Primary Composite Stroke (Fatal/Non-fatal) in patients. The report includes data on the number of events observed for each treatment group and provides a comparison of the hazard ratio between the groups. The data is stratified by age, gender, race, ISH, Diabetes, and History of CVD. The report also includes a comparison of the hazard ratios for each group.*

image005 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 05

image005 - 03375ec9 0e3a 40c2 8c77 de5d9fd21876 05

The text describes the level of risk reduction of a certain treatment or intervention, which is 16.1%. It also includes a statistical value of p=0.022, which may indicate significance or probability. The remaining text appears to be a graph or chart displaying the percentage of patients experiencing an event, but without further context, it is not possible to determine what the event is or how it relates to the other information provided.*

72789282 Label - 72789282

72789282 Label - 72789282

This is a medication called Losartan Potassium USP. It comes in a quantity of 30 tablets, each tablet containing 25mg of the medication. It is for oral ingestion and has a shelf life until December 2023. This medicine should not be taken during pregnancy. The dosage and instructions for use should be prescribed by a physician. It is important to call a doctor for any side effects and it is possible to report side effects to the FDA. The product appears to be from Oklahoma City, OK. No other relevant information could be obtained from the text.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.